Scarica l'app Stockscreener
7.30
2.67%
0.19
Pre-mercato:
8.00
0.70
+9.59%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.11
Aprire:
$7.25
Volume 24 ore:
4.66M
Relative Volume:
2.71
Capitalizzazione di mercato:
$333.44M
Reddito:
$27.10M
Utile/perdita netta:
$-24.31M
Rapporto P/E:
-8.7952
EPS:
-0.83
Flusso di cassa netto:
$-33.33M
1 W Prestazione:
+0.00%
1M Prestazione:
-21.42%
6M Prestazione:
-56.83%
1 anno Prestazione:
+34.19%
Intervallo 1D:
$7.12
$7.90
Intervallo di 1 settimana:
$6.27
$7.90
Portata 52W:
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Nome
Capricor Therapeutics Inc
Settore
Industria
Telefono
(310) 358-3200
Indirizzo
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Confronta CAPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
7.30 | 333.44M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-21 | Iniziato | Piper Sandler | Overweight |
| 2024-05-17 | Iniziato | Oppenheimer | Outperform |
| 2024-01-05 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-26 | Downgrade | Maxim Group | Buy → Hold |
| 2018-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-13 | Ripresa | Rodman & Renshaw | Buy |
| 2016-07-06 | Ripresa | H.C. Wainwright | Buy |
| 2016-06-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
Capricor Therapeutics Inc (CAPR) Q1 2025 Earnings Call Highlight - GuruFocus
Capricor Therapeutics Reports Q1 2025 Financial Results - TipRanks
Capricor: Q1 Earnings Snapshot - The Washington Post
Capricor Therapeutics (CAPR) Highlights Deramiocel Progress in Q - GuruFocus
Earnings call transcript: Capricor Therapeutics Q1 2025 reports wider loss, stock rises - Investing.com Australia
Capricor (CAPR) On Track for Duchenne Cardiomyopathy Therapy App - GuruFocus
Capricor Therapeutics reports Q1 EPS (53c), consensus (32c) - TipRanks
Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Capricor Therapeutics Reports First Quarter 2025 Financial Results And Provides Corporate Update - marketscreener.com
Capricor Therapeutics (CAPR) Sees Elevated Option Activity Ahead of Earnings | CAPR Stock News - GuruFocus
CAPR STOCK ALERT: Levi & Korsinsky Notifies Capricor Therapeutics, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
Capricor Therapeutics (CAPR) Anticipates Q1 Earnings Report - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor - Bluefield Daily Telegraph
Capricor Therapeutics (CAPR) Appoints New Chief Medical Officer - GuruFocus
Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer - The Manila Times
Levi & Korsinsky Reminds Capricor Therapeutics, Inc. Investors of the Ongoing Investigation Into Potential Violations of Securities LawsCAPR - ACCESS Newswire
What To Expect From Capricor Therapeutics Inc (CAPR) Q1 2025 Ear - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire
A Look Ahead: Capricor Therapeutics's Earnings Forecast - Nasdaq
ATTENTION CAPR SHAREHOLDERS: Investors Who Lost Money on Capricor Therapeutics, Inc. are Urged to Contact Levi & Korsinsky about an Ongoing Investigation - ACCESS Newswire
Capricor Therapeutics (CAPR) Projected to Post Earnings on Tuesday - Defense World
CAPR ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Capricor Therapeutics, Inc. - ACCESS Newswire
New FDA Leadership Could Raise The Bar For Drug Approvals - Benzinga
Shareholders that lost money on Capricor Therapeutics, Inc. (CAPR) should contact Levi & Korsinsky about Securities Fraud InvestigationCAPR - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cable One, Inc. - GlobeNewswire Inc.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 26% Price Plummet - simplywall.st
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Capricor Therapeutics, Inc. (CAPR) - ACCESS Newswire
MetLife Investment Management LLC Makes New Investment in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
How the (CAPR) price action is used to our Advantage - news.stocktradersdaily.com
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation - Benzinga
Capricor falls 12% as FDA orders panel to discuss Duchenne cardiomyopathy asset - MSN
Capricor Therapeutics to Present First Quarter 2025 Financial Re - GuruFocus
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 | CAPR Stock News - GuruFocus
Capricor Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on May 13 - Nasdaq
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 - GlobeNewswire
Capricor Therapeutics (CAPR) Faces FDA Advisory Meeting for Duch - GuruFocus
Capricor Therapeutics (CAPR) Faces FDA Advisory Meeting for Duchenne Treatment | CAPR Stock News - GuruFocus
FDA adcomm will review Capricor's cell therapy for Duchenne muscular dystrophy - Endpoints News
US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy - Reuters
Sector Update: Health Care Stocks Lower Monday Afternoon - marketscreener.com
Capricor Therapeutics (CAPR) Faces FDA Advisory Meeting, Shares Drop - GuruFocus
Capricor Therapeutics Shares Fall as FDA Plans Panel Review for Duchenne Treatment - marketscreener.com
Capricor Share Slide 12% as FDA Calls Advisory Panel for Duchenne Cardiomyopathy Therapy - paginasiete.bo
Capricor Therapeutics Stock Tumbles After FDA Confirms Intent To Hold Advisory Committee Meet For Deramiocel Approval: But Retail’s Optimistic - Asianet Newsable
Capricor falls after FDA to hold advisory meeting for cell therapy - TradingView
Capricor Therapeutics (CAPR) Anticipates Positive FDA Review Despite Stock Dip | CAPR Stock News - GuruFocus
CAPR: Capricor Therapeutics Advances FDA Review for Deramiocel | CAPR Stock News - GuruFocus
Capricor Therapeutics Announces Completion of Mid-Cycle - GlobeNewswire
Capricor Therapeutics Inc Azioni (CAPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):